DRI HEALTHCARE TRUST (DHT-U.CA) Fundamental Analysis & Valuation

TSX:DHT-U • CA23344H1091

Current stock price

11.7 USD
-0.1 (-0.85%)
Last:

This DHT-U.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. DHT-U.CA Profitability Analysis

1.1 Basic Checks

  • In the past year DHT-U was profitable.
  • In the past year DHT-U had a positive cash flow from operations.
  • In multiple years DHT-U reported negative net income over the last 5 years.
  • Each year in the past 5 years DHT-U had a positive operating cash flow.
DHT-U.CA Yearly Net Income VS EBIT VS OCF VS FCFDHT-U.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • DHT-U's Return On Assets of -5.35% is in line compared to the rest of the industry. DHT-U outperforms 53.13% of its industry peers.
  • DHT-U has a Return On Equity (-11.51%) which is comparable to the rest of the industry.
  • With a decent Return On Invested Capital value of 4.25%, DHT-U is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for DHT-U is significantly below the industry average of 8.05%.
  • The last Return On Invested Capital (4.25%) for DHT-U is above the 3 year average (2.87%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -5.35%
ROE -11.51%
ROIC 4.25%
ROA(3y)1.76%
ROA(5y)2.41%
ROE(3y)1.4%
ROE(5y)2.6%
ROIC(3y)2.87%
ROIC(5y)2.78%
DHT-U.CA Yearly ROA, ROE, ROICDHT-U.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 5 -5 10 -10 15

1.3 Margins

  • DHT-U's Operating Margin of 26.77% is amongst the best of the industry. DHT-U outperforms 93.75% of its industry peers.
  • DHT-U's Operating Margin has improved in the last couple of years.
  • DHT-U does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 26.77%
PM (TTM) N/A
GM N/A
OM growth 3Y23.29%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DHT-U.CA Yearly Profit, Operating, Gross MarginsDHT-U.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. DHT-U.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DHT-U is destroying value.
  • The number of shares outstanding for DHT-U has been reduced compared to 1 year ago.
  • The debt/assets ratio for DHT-U is higher compared to a year ago.
DHT-U.CA Yearly Shares OutstandingDHT-U.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
DHT-U.CA Yearly Total Debt VS Total AssetsDHT-U.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • DHT-U has an Altman-Z score of 0.81. This is a bad value and indicates that DHT-U is not financially healthy and even has some risk of bankruptcy.
  • DHT-U's Altman-Z score of 0.81 is fine compared to the rest of the industry. DHT-U outperforms 62.50% of its industry peers.
  • DHT-U has a debt to FCF ratio of 4.43. This is a neutral value as DHT-U would need 4.43 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.43, DHT-U is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
  • DHT-U has a Debt/Equity ratio of 0.95. This is a neutral value indicating DHT-U is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.95, DHT-U is doing worse than 68.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 4.43
Altman-Z 0.81
ROIC/WACC0.54
WACC7.88%
DHT-U.CA Yearly LT Debt VS Equity VS FCFDHT-U.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that DHT-U should not have too much problems paying its short term obligations.
  • The Current ratio of DHT-U (1.19) is worse than 71.88% of its industry peers.
  • DHT-U has a Quick Ratio of 1.19. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.19, DHT-U is in line with its industry, outperforming 53.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19
DHT-U.CA Yearly Current Assets VS Current LiabilitesDHT-U.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. DHT-U.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.15% over the past year.
  • The Earnings Per Share has been growing slightly by 6.33% on average over the past years.
  • DHT-U shows a small growth in Revenue. In the last year, the Revenue has grown by 2.28%.
  • DHT-U shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.36% yearly.
EPS 1Y (TTM)4.15%
EPS 3Y6.33%
EPS 5YN/A
EPS Q2Q%1.32%
Revenue 1Y (TTM)2.28%
Revenue growth 3Y29.36%
Revenue growth 5YN/A
Sales Q2Q%-0.94%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.69% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 12.98% on average over the next years. This is quite good.
EPS Next Y1.3%
EPS Next 2Y3.2%
EPS Next 3Y7.76%
EPS Next 5Y16.69%
Revenue Next Year3.88%
Revenue Next 2Y3.92%
Revenue Next 3Y5.54%
Revenue Next 5Y12.98%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DHT-U.CA Yearly Revenue VS EstimatesDHT-U.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
DHT-U.CA Yearly EPS VS EstimatesDHT-U.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

7

4. DHT-U.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 3.76, the valuation of DHT-U can be described as very cheap.
  • 87.50% of the companies in the same industry are more expensive than DHT-U, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of DHT-U to the average of the S&P500 Index (27.38), we can say DHT-U is valued rather cheaply.
  • A Price/Forward Earnings ratio of 3.71 indicates a rather cheap valuation of DHT-U.
  • Based on the Price/Forward Earnings ratio, DHT-U is valued cheaper than 93.75% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 38.20. DHT-U is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 3.76
Fwd PE 3.71
DHT-U.CA Price Earnings VS Forward Price EarningsDHT-U.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DHT-U is valued cheaper than 90.63% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DHT-U is valued cheaply inside the industry as 90.63% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.29
EV/EBITDA 5.95
DHT-U.CA Per share dataDHT-U.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DHT-U does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.9
PEG (5Y)N/A
EPS Next 2Y3.2%
EPS Next 3Y7.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. DHT-U.CA Dividend Analysis

5.1 Amount

  • DHT-U has a Yearly Dividend Yield of 4.57%, which is a nice return.
  • Compared to an average industry Dividend Yield of 0.40, DHT-U pays a better dividend. On top of this DHT-U pays more dividend than 96.88% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, DHT-U pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.57%

5.2 History

  • DHT-U has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
DHT-U.CA Yearly Dividends per shareDHT-U.CA Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2Y3.2%
EPS Next 3Y7.76%
DHT-U.CA Yearly Income VS Free CF VS DividendDHT-U.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

DHT-U.CA Fundamentals: All Metrics, Ratios and Statistics

DRI HEALTHCARE TRUST

TSX:DHT-U (4/15/2026, 7:00:00 PM)

11.7

-0.1 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-11
Inst Owners51.69%
Inst Owner ChangeN/A
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap643.73M
Revenue(TTM)188.92M
Net Income(TTM)-50.47M
Analysts80
Price Target17.76 (51.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.57%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date03-31
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.66%
Min EPS beat(2)-4.46%
Max EPS beat(2)13.79%
EPS beat(4)2
Avg EPS beat(4)-2.8%
Min EPS beat(4)-21.52%
Max EPS beat(4)13.79%
EPS beat(8)5
Avg EPS beat(8)4.54%
EPS beat(12)7
Avg EPS beat(12)13.08%
EPS beat(16)9
Avg EPS beat(16)67.86%
Revenue beat(2)2
Avg Revenue beat(2)11.77%
Min Revenue beat(2)6.93%
Max Revenue beat(2)16.61%
Revenue beat(4)2
Avg Revenue beat(4)5.63%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)16.61%
Revenue beat(8)5
Avg Revenue beat(8)11.32%
Revenue beat(12)9
Avg Revenue beat(12)22.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.37%
PT rev (3m)10.37%
EPS NQ rev (1m)18.21%
EPS NQ rev (3m)-15.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.19%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)5.41%
Revenue NY rev (1m)3.25%
Revenue NY rev (3m)3.26%
Valuation
Industry RankSector Rank
PE 3.76
Fwd PE 3.71
P/S 2.47
P/FCF 4.29
P/OCF 4.25
P/B 1.07
P/tB N/A
EV/EBITDA 5.95
EPS(TTM)3.11
EY26.58%
EPS(NY)3.16
Fwd EY26.97%
FCF(TTM)2.73
FCFY23.33%
OCF(TTM)2.75
OCFY23.54%
SpS4.73
BVpS10.99
TBVpS-8.5
PEG (NY)2.9
PEG (5Y)N/A
Graham Number27.7261 (136.98%)
Profitability
Industry RankSector Rank
ROA -5.35%
ROE -11.51%
ROCE 5.91%
ROIC 4.25%
ROICexc 4.47%
ROICexgc 100.55%
OM 26.77%
PM (TTM) N/A
GM N/A
FCFM 57.68%
ROA(3y)1.76%
ROA(5y)2.41%
ROE(3y)1.4%
ROE(5y)2.6%
ROIC(3y)2.87%
ROIC(5y)2.78%
ROICexc(3y)3.02%
ROICexc(5y)3.02%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.99%
ROCE(5y)3.9%
ROICexgc growth 3Y91.89%
ROICexgc growth 5YN/A
ROICexc growth 3Y42.55%
ROICexc growth 5YN/A
OM growth 3Y23.29%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 4.43
Debt/EBITDA 2.73
Cap/Depr 0.97%
Cap/Sales 0.52%
Interest Coverage 250
Cash Conversion 72.08%
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z 0.81
F-Score4
WACC7.88%
ROIC/WACC0.54
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.15%
EPS 3Y6.33%
EPS 5YN/A
EPS Q2Q%1.32%
EPS Next Y1.3%
EPS Next 2Y3.2%
EPS Next 3Y7.76%
EPS Next 5Y16.69%
Revenue 1Y (TTM)2.28%
Revenue growth 3Y29.36%
Revenue growth 5YN/A
Sales Q2Q%-0.94%
Revenue Next Year3.88%
Revenue Next 2Y3.92%
Revenue Next 3Y5.54%
Revenue Next 5Y12.98%
EBIT growth 1Y16.2%
EBIT growth 3Y59.49%
EBIT growth 5YN/A
EBIT Next Year142.04%
EBIT Next 3Y39.91%
EBIT Next 5Y34.01%
FCF growth 1Y-29.89%
FCF growth 3Y12.04%
FCF growth 5YN/A
OCF growth 1Y-29.25%
OCF growth 3Y12.38%
OCF growth 5YN/A

DRI HEALTHCARE TRUST / DHT-U.CA Fundamental Analysis FAQ

What is the fundamental rating for DHT-U stock?

ChartMill assigns a fundamental rating of 5 / 10 to DHT-U.CA.


What is the valuation status of DRI HEALTHCARE TRUST (DHT-U.CA) stock?

ChartMill assigns a valuation rating of 7 / 10 to DRI HEALTHCARE TRUST (DHT-U.CA). This can be considered as Undervalued.


What is the profitability of DHT-U stock?

DRI HEALTHCARE TRUST (DHT-U.CA) has a profitability rating of 4 / 10.


How financially healthy is DRI HEALTHCARE TRUST?

The financial health rating of DRI HEALTHCARE TRUST (DHT-U.CA) is 3 / 10.